Telix Pharmaceuticals Limited (ASX:TLX)
Australia · Delayed Price · Currency is AUD 16.19
+1.15 (7.65%)
Aug 7, 2026, 4:10 PM AEST
Telix Pharmaceuticals Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 803.79 | 803.79 | 516.55 | 332.98 | 108.81 | 5.52 |
Revenue Growth | 21.01% | 55.61% | 55.13% | 206.01% | 1870.12% | 37.33% |
Gross Profit Gross Profit Growth | 381.85 | 381.85 | 319.49 | 203.28 | 64.52 | 3.67 |
Operating Income Operating Income Growth | 19.29 | 19.29 | 55.88 | 34.98 | -50.37 | -59.08 |
Net Income Net Income Growth | -7.13 | -7.13 | 33.69 | 4.21 | -70.74 | -58.54 |
Earnings Per Share EPS Growth | -0.02 | -0.02 | 0.10 | 0.01 | -0.23 | -0.21 |
EPS Growth | - | - | 650.77% | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 |
Precision Medicine Precision Medicine Growth | 621.93 | 621.93 | 508.51 | 329.21 |
Therapeutics Therapeutics Growth | 9.27 | 9.27 | 6.23 | 3.5 |
Manufacturing Solutions Manufacturing Solutions Growth | 245.11 | 245.11 | 1.82 | 0.28 |
Inter-Segment Elimination Inter-Segment Elimination Growth | -72.51 | -72.51 | - | - |
Total Total Growth | 803.79 | 803.79 | 516.55 | 332.98 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 141.87 | 141.87 | 440 | 84.3 | 79.07 | 16.02 |
Total Debt Total Debt Growth | 467.11 | 467.11 | 360.16 | 12.26 | 7.1 | 1.85 |
Net Cash (Debt) Net Cash Growth | -325.24 | -325.24 | 79.84 | 72.03 | 71.97 | 14.18 |
Net Cash Growth | - | - | 10.84% | 0.09% | 407.61% | -75.74% |
Net Cash Per Share Net Cash Per Share Growth | -0.96 | -0.96 | 0.23 | 0.22 | 0.23 | 0.05 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -17.29 | -17.29 | 27.49 | 14.27 | -43.48 | -43.14 |
Capital Expenditures CapEx Growth | -25.69 | -25.69 | -9.12 | -6.31 | -4.78 | -0.97 |
Free Cash Flow Free Cash Flow Growth | -42.99 | -42.99 | 18.37 | 7.97 | -48.26 | -44.11 |
Free Cash Flow Growth | - | - | 130.64% | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 47.50% | 47.50% | 61.85% | 61.05% | 59.29% | 66.46% |
Operating Margin | 2.40% | 2.40% | 10.82% | 10.51% | -46.29% | -1069.60% |
Pretax Margin | -0.66% | -0.66% | 7.34% | 0.78% | -61.60% | -1059.31% |
Profit Margin | -0.89% | -0.89% | 6.52% | 1.26% | -65.01% | -1059.90% |
FCF Margin | -5.35% | -5.35% | 3.56% | 2.39% | -44.35% | -798.67% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 151.34 | 528.32 | - | - |
Forward PE | 1266.75 | 282.12 | 87.27 | 32.83 | - | - |
P/FCF Ratio | - | - | 277.46 | 279.08 | - | - |
PS Ratio | 4.24 | 3.15 | 9.87 | 6.68 | 14.37 | 290.85 |